Anna Sommerfeld
Anna Sommerfeld is a molecular biologist by training and has more than 25 years of experience in the pharmaceutical industry, including roles at AstraZeneca, Roche and Gilead Sciences. As the founder of Mealsizer®, she has spent the past 14 years working closely with both obesity and eating disorder care, translating research into practical solutions for better health.
Sustainable Weight Loss and Health Benefits in Obesity Care: 18-Month Real-World-Evaluation Results in a Virtual Care Setting from Yazens First Operational Quality follow-up
This 18-month real-world evaluation data analysis demonstrates that Yazen Health’s fully digital care model, integrating pharmacological treatment and lifestyle intervention can provide effective, sustainable results in a real-world setting.
Summary
Patients achieved a weight reduction of 16.6%, accompanied by improvements in metabolic health markers including laboratory values, despite medication supply limitations and without using the maximum recommended dose of semaglutide. 70% remained in the program after 12 months. Weight loss outcomes were comparable to those observed in RCTs such as the STEP trials1-2.
.webp)
High Adherence to GLP-1 Receptor Agonists: 18-Month Outcomes from the Yazen Model
High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
Summary
This real-world analysis from Yazens first large scale operational quality follow-up, demonstrates almost 70% compliance with GLP-1 medications at 12 months, surpassing earlier studies that showed 20-50%1-4. After 2 years*, 60% of patients were still in treatment.
.webp)
The Yazen Model - Modern Obesity Treatment Given Via a Digital Care Model. A Descriptive Analysis
The Yazen Model enables modern obesity treatment, integrating medical treatment, lifestyle intervention and social support. By now*, more than 30,000 patients have received treatment using this model.
Summary
The Yazen Model goes beyond traditional methods, providing patients with the tools to manage their disease, addressing medical and behavioural aspects, education and social support via a digital platform for accessible, continuous and effective weight loss and management.
